Neuland Laboratories Ltd Share Price

Neuland Laboratories: Land-Banking company

CMP: ₹23,995 - a new high, near/above the previous 52-week high (₹23,899) Price Movement: The stock has more than doubled over the past year (from a 52-week low of ₹11,500), with strong 1-month momentum. It's now trading at fresh highs, and technicals have stayed bullish with RSI readings near overbought territory.

's board approved ₹126 crore to acquire 134 acres in Kakinada, Andhra Pradesh (plus ROFR on 66 more acres), funded entirely through internal accruals, no debt, no dilution. Positives: Debt-free capacity planning, strong multi-year price trend, sustained institutional confidence. Concerns: No disclosed plant timeline or capex plan yet, this is land-banking, not new output. Valuation is rich (PE 50-60x+), and the stock is at all-time highs, leaving little margin of safety. Why it stands out right now: Tomorrow, September 9, is confirmed as a genuinely rare event - six mainboard IPOs open on the same day, together raising roughly ₹4,400–4,500 crore. Multiple sources describe this as the biggest single-day IPO rush in 30 years.

See More

Neuland Laboratories: ₹126 Cr Land Acquisition

is in focus after its board approved a ₹126 crore capital expenditure for the purchase of approximately 134 acres of land at Kakinada, Andhra Pradesh. The company has also secured a right of first refusal to acquire an additional contiguous land parcel of approximately 66 acres at a later stage, which could take the potential aggregate land holding at the location to around 200 acres. Neuland Laboratories has indicated that the land is intended to support the company’s future expansion plans. The acquisition provides the company with additional land capacity for potential development and expansion of its operations in the future. Investors will be watching how the company plans to utilise the land, the timing of subsequent development and the capital expenditure associated with future projects. The announcement puts Neuland Laboratories in focus as the company moves ahead with its longer-term expansion plans.

See More

Neuland Laboratories in Focus After Expansion Plan

Neuland Laboratories is in focus after its board approved a ₹126 crore capital expenditure for acquiring approximately 134 acres of land at Auro Industrial City in Kakinada, Andhra Pradesh. The company plans to use the land for its future expansion requirements, providing a potential foundation for additional manufacturing and business capacity. The entire investment will be funded through internal accruals, meaning the company does not need to depend on fresh debt for the acquisition. Neuland has also secured a right of first refusal for another contiguous parcel of around 66 acres, which could eventually take its total land holding at the location to nearly 200 acres. The expansion plan indicates that the company is preparing for longer-term growth and capacity requirements. Investors are likely to monitor how the land is subsequently utilised and whether new manufacturing facilities or other expansion projects are announced. The use of internal accruals also keeps the balance sheet impact relatively manageable. The development could provide a positive long-term trigger for the stock, while execution and future capital deployment will remain important factors.

See More

Neuland Laboratories in Focus After ₹126 Cr Expansion Bet

Neuland Laboratories is in focus on September 8 after approving ₹126 crore capex for 134 acres in Kakinada. The stock has gained 50.46% YTD in CY2026. Neuland Laboratories Ltd. (NSE:

) could be in focus today, September 8, 2026, after the company announced a major expansion move in Andhra Pradesh. The company’s Board has approved ₹126 crore in capital expenditure to purchase approximately 134 acres of land in Kakinada. Neuland also has a right of first refusal to acquire another contiguous parcel of around 66 acres, potentially taking its total landholding at the location to nearly 200 acres. According to the company, the land acquisition is intended to support its future expansion plans. The announcement comes after a strong run in the stock. Neuland Laboratories shares closed at ₹22,870 on September 7, up 0.93% for the day. The stock’s 52-week high stands at ₹23,881. Neuland Laboratories has gained an impressive 50.46% year-to-date in CY2026, while rising 13.55% over the past month. However, the stock declined 2.35% during the last one week. With a market capitalisation of ₹29,368 crore and a P/E ratio of 59, investors may watch whether the expansion announcement acts as another catalyst for the stock in the coming sessions. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More

A strong stock can outperform a weak market.

industry growth, earnings momentum, and investor confidence align together. Imagine the market is walking through a storm. The Nifty is under pressure, crude oil is rising, and sentiment is cautious. Yet, some companies continue climbing. **Sai Life Sciences** is one such example. On September 2, the Nifty 500 environment remained weak, while Sai Life Sciences touched a new lifetime high of ₹1,578 and gained about 8% across two sessions. Its trading volume also more than doubled. Sai Life Sciences operates in the **CRDMO** space—helping pharmaceutical and biotechnology companies with research, development and manufacturing. The larger opportunity comes from increasing global pharma outsourcing and demand for specialised therapies. The interesting part is that this is not an isolated industry story. Other **Nifty 500** healthcare names such as **Divi’s Laboratories, Laurus Labs, Gland Pharma and Neuland Laboratories** also provide useful examples for studying the CRDMO/pharma outsourcing theme. Business Standard has previously highlighted Sai Life Sciences, Laurus Labs and Divi’s Laboratories among stocks reaching fresh highs. 🔎 **What should a learner study?** • Revenue and profit growth • Order-book visibility • Industry CAGR and outsourcing trends • Operating margins • Valuation versus peers • Volume confirmation during price moves The lesson is simple: **when the market struggles, study the businesses that continue demonstrating fundamental strength—but never confuse relative strength with a guaranteed future return.**

, Divi’s Laboratories, Laurus Labs, Gland Pharma, Neuland Laboratories. ⚠️ **Disclaimer:** This post is strictly for educational purposes and is **not investment advice, a stock recommendation, or a buy/sell/hold call**. Do your own research and consult a SEBI-registered investment professional before making investment decisions.

See More

📊 COMPANIES WITH STRONG RESULTS (NEHA GUPTA SEBI RA)

📊 COMPANIES WITH STRONG RESULTS 1️⃣ Power, Electrical & Energy POLYCAB • SIEMENS • POWERINDIA • APARINDS • TDPOWERSYS • PREMIERENE • QPOWER

2️⃣ Automobile & Auto Components BAJAJ-AUTO • TVSMOTOR • CRAFTSMAN • SJS • ATHERENERG • GNA • MTARTECH 3️⃣ Jewellery & Precious Metals TITAN • KALYANKJIL • BLUESTONE • PNGJL • SKYGOLD • PNGSREVA 4️⃣ IT, AI & Digital Technology NETWEB • E2E • TATATECH • HFCL • SYRMA • CYIENTDLM • STLTECH 5️⃣ Pharma & Life Sciences LAURUSLABS • GLAND • SAILIFE • NAVINFLUOR • NEULANDLAB • AARTIPHARM • SHILPAMED 6️⃣ Banking, NBFC & Financial Services ICICIBANK • IDFCFIRSTB • SHRIRAMFIN • CHOLAFIN • FEDERALBNK • LTF • POONAWALLA 📌 Strong results ≠ automatic buy. Always evaluate valuation, growth, risk & market conditions before taking any investment decision. #StockMarket #IndianStocks #NSE #BSE #Stocks #Investing #StockMarketIndia #Results #Earnings #SwingTrading

See More